Do analysts rate STEX or BDMD?

Biosig Technologies currently has a consensus target price of $8.00, suggesting a potential upside of 863.86%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Biosig Technologies is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biosig Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, STEX or BDMD?

Baird Medical Investment has higher revenue and earnings than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biosig Technologies $40K 3,772.35 -$462.77M -$9.71 N/A Baird Medical Investment $22.54M 2.25 N/A N/A N/A

Is STEX or BDMD more profitable?

Baird Medical Investment's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Biosig Technologies N/A -717.92% -336.75% Baird Medical Investment N/A N/A N/A

Does the media favor STEX or BDMD?

In the previous week, Baird Medical Investment had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Baird Medical Investment and 2 mentions for Biosig Technologies. Baird Medical Investment's average media sentiment score of 1.43 beat Biosig Technologies' score of 0.93 indicating that Baird Medical Investment is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baird Medical Investment 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HYPR or BDMD?

Hyperfine currently has a consensus price target of $1.78, suggesting a potential upside of 24.27%. Given Hyperfine's stronger consensus rating and higher probable upside, equities analysts plainly believe Hyperfine is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperfine 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, HYPR or BDMD?

Baird Medical Investment has higher revenue and earnings than Hyperfine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 12.50 -$35.57M -$0.41 N/A Baird Medical Investment $22.54M 2.25 N/A N/A N/A

Does the media favor HYPR or BDMD?

In the previous week, Hyperfine and Hyperfine both had 3 articles in the media. Baird Medical Investment's average media sentiment score of 1.43 beat Hyperfine's score of 0.62 indicating that Baird Medical Investment is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baird Medical Investment 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BDMD or CVRX?

CVRx has a consensus target price of $11.50, indicating a potential upside of 101.19%. Given CVRx's stronger consensus rating and higher possible upside, analysts plainly believe CVRx is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CVRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has better valuation & earnings, BDMD or CVRX?

Baird Medical Investment has higher earnings, but lower revenue than CVRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baird Medical Investment $22.54M 2.25 N/A N/A N/A CVRx $56.65M 2.68 -$53.31M -$2.02 N/A

Does the media favor BDMD or CVRX?

In the previous week, Baird Medical Investment had 1 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Baird Medical Investment and 2 mentions for CVRx. Baird Medical Investment's average media sentiment score of 1.43 beat CVRx's score of 0.94 indicating that Baird Medical Investment is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baird Medical Investment 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CVRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BDMD or GUTS?

Fractyl Health has a consensus target price of $5.40, suggesting a potential upside of 597.67%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fractyl Health 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation and earnings, BDMD or GUTS?

Baird Medical Investment has higher revenue and earnings than Fractyl Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baird Medical Investment $22.54M 2.25 N/A N/A N/A Fractyl Health N/A N/A -$140.95M -$1.29 N/A

Is BDMD or GUTS more profitable?

Baird Medical Investment's return on equity of 0.00% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Baird Medical Investment N/A N/A N/A Fractyl Health N/A -4,053.15% -96.41%

Do analysts prefer BDMD or MBOT?

Microbot Medical has a consensus target price of $6.63, indicating a potential upside of 267.04%. Given Microbot Medical's stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Microbot Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has higher valuation and earnings, BDMD or MBOT?

Baird Medical Investment has higher revenue and earnings than Microbot Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baird Medical Investment $22.54M 2.25 N/A N/A N/A Microbot Medical N/A N/A -$13.14M -$0.26 N/A

Is BDMD or MBOT more profitable?

Baird Medical Investment's return on equity of 0.00% beat Microbot Medical's return on equity. Company Net Margins Return on Equity Return on Assets Baird Medical Investment N/A N/A N/A Microbot Medical N/A -21.84% -20.71%

Does the media refer more to BDMD or MBOT?

In the previous week, Baird Medical Investment and Baird Medical Investment both had 3 articles in the media. Baird Medical Investment's average media sentiment score of 1.43 beat Microbot Medical's score of 0.62 indicating that Baird Medical Investment is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baird Medical Investment 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Microbot Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Baird Medical Investment (BDMD) Competitors

$1.24 +0.18 (+16.51%)

As of 09:40 AM Eastern

Compare

BDMD vs. STEX, HYPR, CVRX, GUTS, and MBOT

Should you buy Baird Medical Investment stock or one of its competitors? MarketBeat compares Baird Medical Investment with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Baird Medical Investment include Biosig Technologies (STEX), Hyperfine (HYPR), CVRx (CVRX), Fractyl Health (GUTS), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.

How does Baird Medical Investment compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Baird Medical Investment had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Baird Medical Investment and 2 mentions for Biosig Technologies. Baird Medical Investment's average media sentiment score of 1.43 beat Biosig Technologies' score of 0.93 indicating that Baird Medical Investment is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baird Medical Investment	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biosig Technologies currently has a consensus target price of $8.00, suggesting a potential upside of 863.86%. Given Biosig Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Biosig Technologies is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Baird Medical Investment's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Baird Medical Investment	N/A	N/A	N/A

Biosig Technologies has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.22, indicating that its stock price is 222% less volatile than the broader market.

Baird Medical Investment has higher revenue and earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	3,772.35	-$462.77M	-$9.71	N/A
Baird Medical Investment	$22.54M	2.25	N/A	N/A	N/A

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Baird Medical Investment beats Biosig Technologies on 7 of the 12 factors compared between the two stocks.

How does Baird Medical Investment compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Hyperfine currently has a consensus price target of $1.78, suggesting a potential upside of 24.27%. Given Hyperfine's stronger consensus rating and higher probable upside, equities analysts plainly believe Hyperfine is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Baird Medical Investment has a net margin of 0.00% compared to Hyperfine's net margin of -226.88%. Baird Medical Investment's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Baird Medical Investment	N/A	N/A	N/A

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 78.9% of Baird Medical Investment shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hyperfine and Hyperfine both had 3 articles in the media. Baird Medical Investment's average media sentiment score of 1.43 beat Hyperfine's score of 0.62 indicating that Baird Medical Investment is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baird Medical Investment	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Baird Medical Investment has higher revenue and earnings than Hyperfine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A
Baird Medical Investment	$22.54M	2.25	N/A	N/A	N/A

Hyperfine has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market.

Summary

Baird Medical Investment beats Hyperfine on 7 of the 12 factors compared between the two stocks.

How does Baird Medical Investment compare to CVRx?

Baird Medical Investment (NASDAQ:BDMD) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

In the previous week, Baird Medical Investment had 1 more articles in the media than CVRx. MarketBeat recorded 3 mentions for Baird Medical Investment and 2 mentions for CVRx. Baird Medical Investment's average media sentiment score of 1.43 beat CVRx's score of 0.94 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baird Medical Investment	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Baird Medical Investment has a net margin of 0.00% compared to CVRx's net margin of -89.14%. Baird Medical Investment's return on equity of 0.00% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
CVRx	-89.14%	-120.76%	-48.38%

Baird Medical Investment has higher earnings, but lower revenue than CVRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54M	2.25	N/A	N/A	N/A
CVRx	$56.65M	2.68	-$53.31M	-$2.02	N/A

CVRx has a consensus target price of $11.50, indicating a potential upside of 101.19%. Given CVRx's stronger consensus rating and higher possible upside, analysts plainly believe CVRx is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by insiders. Comparatively, 18.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Baird Medical Investment has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, CVRx has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Summary

CVRx beats Baird Medical Investment on 8 of the 14 factors compared between the two stocks.

How does Baird Medical Investment compare to Fractyl Health?

Baird Medical Investment (NASDAQ:BDMD) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Baird Medical Investment has a beta of -1.22, meaning that its share price is 222% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

Baird Medical Investment has higher revenue and earnings than Fractyl Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54M	2.25	N/A	N/A	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$1.29	N/A

In the previous week, Baird Medical Investment had 2 more articles in the media than Fractyl Health. MarketBeat recorded 3 mentions for Baird Medical Investment and 1 mentions for Fractyl Health. Fractyl Health's average media sentiment score of 1.87 beat Baird Medical Investment's score of 1.43 indicating that Fractyl Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Baird Medical Investment	Positive
Fractyl Health	Very Positive

Baird Medical Investment's return on equity of 0.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Fractyl Health	N/A	-4,053.15%	-96.41%

19.8% of Baird Medical Investment shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 8.5% of Fractyl Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fractyl Health has a consensus target price of $5.40, suggesting a potential upside of 597.67%. Given Fractyl Health's stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Baird Medical Investment beats Fractyl Health on 6 of the 11 factors compared between the two stocks.

How does Baird Medical Investment compare to Microbot Medical?

Baird Medical Investment (NASDAQ:BDMD) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 4.7% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Baird Medical Investment has higher revenue and earnings than Microbot Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54M	2.25	N/A	N/A	N/A
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A

In the previous week, Baird Medical Investment and Baird Medical Investment both had 3 articles in the media. Baird Medical Investment's average media sentiment score of 1.43 beat Microbot Medical's score of 0.62 indicating that Baird Medical Investment is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baird Medical Investment	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Microbot Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Baird Medical Investment's return on equity of 0.00% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Microbot Medical	N/A	-21.84%	-20.71%

Microbot Medical has a consensus target price of $6.63, indicating a potential upside of 267.04%. Given Microbot Medical's stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Baird Medical Investment has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Summary

Baird Medical Investment beats Microbot Medical on 6 of the 11 factors compared between the two stocks.

Get Baird Medical Investment News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDMD vs. The Competition

Export

Metric	Baird Medical Investment	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.68M	$7.36B	$6.83B	$12.17B
Dividend Yield	N/A	1.24%	2.66%	6.11%
P/E Ratio	N/A	51.24	25.88	24.17
Price / Sales	2.25	48.56	550.12	99.13
Price / Cash	N/A	26.99	29.09	36.93
Price / Book	N/A	7.53	10.76	6.38
Net Income	N/A	$159.19M	$3.58B	$337.00M
7 Day Performance	16.51%	2.61%	1.93%	-0.23%
1 Month Performance	-17.11%	-2.37%	-0.23%	-1.40%
1 Year Performance	-68.33%	5.96%	34.40%	27.76%

Baird Medical Investment Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDMD Baird Medical Investment	1.5181 of 5 stars	$1.24 +16.5%	N/A	-72.8%	$46.68M	$22.54M	N/A	N/A	News Coverage Positive News Short Interest Decrease Gap Down
STEX Biosig Technologies	2.2061 of 5 stars	$0.80 -6.7%	$8.00 +897.5%	N/A	$146.17M	N/A	N/A	50	News Coverage Gap Down
HYPR Hyperfine	2.6393 of 5 stars	$1.45 -1.7%	$1.78 +23.4%	+98.9%	$144.44M	$15.33M	N/A	190	News Coverage Gap Up
CVRX CVRx	3.1038 of 5 stars	$5.24 +1.7%	$11.50 +119.5%	+0.7%	$139.45M	$59.07M	N/A	160	News Coverage Analyst Upgrade
GUTS Fractyl Health	4.4261 of 5 stars	$0.79 -4.1%	$5.40 +581.0%	-54.7%	$127.24M	$90K	N/A	102	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDMD) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Baird Medical Investment (BDMD) Competitors

BDMD vs. STEX, HYPR, CVRX, GUTS, and MBOT

How does Baird Medical Investment compare to Biosig Technologies?

Summary

How does Baird Medical Investment compare to Hyperfine?

Summary

How does Baird Medical Investment compare to CVRx?

Summary

How does Baird Medical Investment compare to Fractyl Health?

Summary

How does Baird Medical Investment compare to Microbot Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDMD vs. The Competition

Baird Medical Investment Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Baird Medical Investment (BDMD) Competitors

BDMD vs. STEX, HYPR, CVRX, GUTS, and MBOT

How does Baird Medical Investment compare to Biosig Technologies?

Does the media favor STEX or BDMD?

Do analysts rate STEX or BDMD?

Is STEX or BDMD more profitable?

Which has more risk & volatility, STEX or BDMD?

Which has better valuation and earnings, STEX or BDMD?

Do institutionals & insiders hold more shares of STEX or BDMD?

Summary

How does Baird Medical Investment compare to Hyperfine?

Do analysts prefer HYPR or BDMD?

Is HYPR or BDMD more profitable?

Do institutionals & insiders have more ownership in HYPR or BDMD?

Does the media favor HYPR or BDMD?

Which has preferable earnings & valuation, HYPR or BDMD?

Which has more volatility & risk, HYPR or BDMD?

Summary

How does Baird Medical Investment compare to CVRx?

Does the media favor BDMD or CVRX?

Is BDMD or CVRX more profitable?

Which has better valuation & earnings, BDMD or CVRX?

Do analysts recommend BDMD or CVRX?

Do insiders & institutionals believe in BDMD or CVRX?

Which has more risk & volatility, BDMD or CVRX?

Summary

How does Baird Medical Investment compare to Fractyl Health?

Which has more volatility & risk, BDMD or GUTS?

Which has better valuation and earnings, BDMD or GUTS?

Does the media refer more to BDMD or GUTS?

Is BDMD or GUTS more profitable?

Do institutionals and insiders have more ownership in BDMD or GUTS?

Do analysts recommend BDMD or GUTS?

Summary

How does Baird Medical Investment compare to Microbot Medical?

Do insiders and institutionals hold more shares of BDMD or MBOT?

Which has higher valuation and earnings, BDMD or MBOT?

Does the media refer more to BDMD or MBOT?

Is BDMD or MBOT more profitable?

Do analysts prefer BDMD or MBOT?

Which has more risk & volatility, BDMD or MBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDMD vs. The Competition

Baird Medical Investment Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools